Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Selecting the right anticoagulant for stroke prevention in atrial fibrillation
CONCLUSIONS: Non-valvular AF patients on apixaban had lower rates of thromboembolic events than the patients on acenocumarol. This article will serve as a reminder of the positive health and financial outcomes of apixaban use, especially to those healthcare systems that are still oblivious to the decrease in economic burden and gain in quality-adjusted life years (QALY) by the long-term use of NOACS/ DOACS instead of the AVK anticoagulants.PMID:34286492 | DOI:10.26355/eurrev_202107_26241
Source: European Review for Medical and Pharmacological Sciences - July 21, 2021 Category: Drugs & Pharmacology Authors: N R Kundnani C I Rosca A Sharma A Tudor M S Rosca D D Nisulescu H S Branea V Mocanu D C Crisan D R Buzas S Morariu D F Lighezan Source Type: research

Retracted Note: Effects of Vitamin K2 on Osteoporosis
Curr Pharm Des. 2021;27(19):2325. doi: 10.2174/138161282719210608092930.ABSTRACTThe article entitled "Effects of Vitamin K2 on Osteoporosis, published in Curr Pharm Des 2004; 10(21): 2557-76, by Iwamoto J, Takeda T and Sato Y." has been retracted by the Editorial office of the journal Current Pharmaceutical Design, as the text, data and some figures used/referred in this review article are from sources which have been retracted or under investigation on the basis of data fabrication and falsification, authorship misconduct, duplicate publication, unethical research practices, text recycling/self-plagiarism, and unresolved ...
Source: Current Pharmaceutical Design - July 15, 2021 Category: Drugs & Pharmacology Authors: Jun Iwamoto Tsuyoshi Takeda Yoshihiro Sato Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis
Conclusions: DOACs seem to be more efficacious in achieving LVT resolution compared with VKAs. However, there was no significant difference between the 2 groups in thromboembolic events, major bleeding, and all-cause mortality. Randomized controlled trials are needed to confirm our findings.
Source: American Journal of Therapeutics - July 1, 2021 Category: Drugs & Pharmacology Tags: Meta-analysis Source Type: research

Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Conclusions Overall, we found a moderate signal of higher frequency of reporting hemorrhage in rivaroxban compared with dabigatran and decreased hemorrhagic event reporting in apixaban compared with dabigatran. While this potential signal has not been confirmed in clinical trials or observational studies, in clinical practice, attention should be paid to the risk of potential hemorrhage when the patients switch from apixaban to dabigatran or rivaroxban.
Source: International Journal of Clinical Pharmacy - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to prevent and treat venous thromboembolism. Despite their widespread use in clinical practice, there are still some unresolved issues on optimizing their use in particular clinical settings. Herein, we reviewed the current clinical evidence on uses of DOACs from pharmacology and clinical indications to safety and practical issues such as drugs and food interactions. Dabigatran is the DOAC most affected by interactions with drugs and food, although all...
Source: Frontiers in Pharmacology - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
AbstractVitamin K antagonists have been used for many years as the treatment of choice for long-term oral anticoagulation in patients with non-valvular atrial fibrillation. Unfortunately, the use of those drugs in the real-world setting, particularly among elderly patients, is suboptimal because of their limitations in management. Therefore, many patients were not adequately anticoagulated. Direct oral anticoagulants have been demonstrated to overcome almost all the limitations derived from the use of vitamin K antagonists. Direct oral anticoagulants are at least as effective as vitamin K antagonists in preventing thromboe...
Source: Advances in Therapy - May 21, 2021 Category: Drugs & Pharmacology Source Type: research

Use of Non-Vitamin  K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
ConclusionsAmong patients with NVAF and six or more comorbid conditions, NOACs were associated with varying risk of stroke/SE and MB compared to warfarin and to each other. Rather than a “one drug fits all” approach, our results may be useful for appropriate OAC treatment for multimorbid patients.
Source: Advances in Therapy - May 7, 2021 Category: Drugs & Pharmacology Source Type: research